Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
25 juil. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
09 juil. 2024 03h01 HE
|
Mainz BioMed NV
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Provides Half Year 2024 Corporate Update
02 juil. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Provides Half Year 2024 Corporate Update -
Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
03 juin 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed Reports Results of 2024 Annual General Meeting
31 mai 2024 17h01 HE
|
Mainz BioMed NV
Mainz Biomed Reports Results of 2024 Annual General Meeting
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
28 mai 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
20 mai 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
07 mai 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
25 avr. 2024 09h29 HE
|
Mainz BioMed NV
Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
Mainz Biomed Reports Full Year 2023 Financial Results
09 avr. 2024 08h01 HE
|
Mainz BioMed NV
Mainz Biomed Reports Full Year 2023 Financial Results